A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Margaret E Gatti-MaysJulius StraussRenee N DonahueClaudia PalenaJaydira Del RiveroJason Mark RedmanRavi A MadanJennifer L MartéLisa M CordesElizabeth LampingAlanvin OrpiaAndrea BurmeisterEva WagnerCesar Pico NavarroChristopher R HeeryJeffrey SchlomJames L GulleyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The BN-CV301 vaccine can be safely administered to patients with advanced cancer. Further studies of the vaccine in combination with other agents are planned.See related commentary by Repáraz et al., p. 4871.